Longitudinal analysis of SARS-CoV-2 IgG antibody durability in Puerto Rico
Open Access
- 28 December 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-13
Abstract
Understanding the dynamics of antibody responses following vaccination and SARS-CoV-2 infection is important for informing effective vaccination strategies and other public health interventions. This study investigates SARS-CoV-2 antibody dynamics in a Puerto Rican cohort, analyzing how IgG levels vary by vaccination status and previous infection. We assess waning immunity and the distribution of hybrid immunity with the aim to inform public health strategies and vaccination programs in Puerto Rico and similar settings. We conducted a prospective, longitudinal cohort study to identify SARS-CoV-2 infections and related outcomes in Ponce, Puerto Rico, from June 2020–August 2022. Participants provided self-collected nasal swabs every week and serum every six months for RT-PCR and IgG testing, respectively. IgG reactivity against nucleocapsid (N) antigens, which generally indicate previous infection, and spike (S1) and receptor-binding domain (RBD) antigens, which indicate history of either infection or vaccination, was assessed using the Luminex Corporation xMAP® SARS-CoV-2 Multi-Antigen IgG Assay. Prior infection was defined by positive RT-PCRs, categorized by the predominant circulating SARS-CoV-2 variant at the event time. Demographic information, medical history, and COVID-19 vaccination history were collected through standardized questionnaires. Of 882 participants included in our analysis, 34.0% experienced at least one SARS-CoV-2 infection, with most (78.7%) occurring during the Omicron wave (December 2021 onwards). SARS-CoV-2 antibody prevalence increased over time, reaching 98.4% by the final serum collection, 67.0% attributable to vaccination alone, 1.6% from infection alone, and 31.4% from both. Regardless of prior infection status, RBD and S1 IgG levels gradually declined following two vaccine doses. A third dose boosted these antibody levels and showed a slower decline over time. N-antibody levels peaked during the Omicron surge and waned over time. Vaccination in individuals with prior SARS-CoV-2 infection elicited the highest and most durable antibody responses. N or S1 seropositivity was associated with lower odds of a subsequent positive PCR test during the Omicron period, with N antibodies showing a stronger association. By elucidating the differential decay of RBD and S1 antibodies following vaccination and the complexities of N-antibody response following infection, this study in a Puerto Rican cohort strengthens the foundation for developing targeted interventions and public health strategies.Keywords
Funding Information
- Centers for Disease Control and Prevention (U01CK000580)
This publication has 59 references indexed in Scilit:
- Inpatient Costs of Treating Patients With COVID-19JAMA Network Open, 2024
- Evaluation of Waning of SARS-CoV-2 Vaccine–Induced ImmunityJAMA Network Open, 2023
- Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative ReviewInfectious Diseases and Therapy, 2023
- Enhanced SARS-CoV-2 IgG durability following COVID-19 mRNA booster vaccination and comparison of BNT162b2 with mRNA-1273Annals of Allergy, Asthma & Immunology, 2022
- Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron InfectionJAMA Network Open, 2022
- Replication of SARS-CoV-2 Omicron BA.2 variant in ex vivo cultures of the human upper and lower respiratory tractEBioMedicine, 2022
- Household Secondary Attack Rates of SARS-CoV-2 by Variant and Vaccination StatusJAMA Network Open, 2022
- Long-Term Persistence of Anti-SARS-COV-2 IgG AntibodiesCurrent Microbiology, 2022
- Antibody response following SARS-CoV-2 vaccination among patients with type 2 diabetes mellitus: A systematic reviewDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2022
- Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 VaccineJAMA Network Open, 2021